P-FIQ Study Highlights Pain Issues in PWH
P-FIQ Study Reports on Acute and Chronic Pain in Adults with Hemophilia
THSNA 2016 (Chicago, April 14-16): Joint pain is a common problem for adults with hemophilia, but recent data from the Pain, Functional Impairment and Quality of Life (P-FIQ) study presented at the Thrombosis and Hemostasis Summit of North America (THSNA) highlight specific issues around acute and chronic pain. Adult males with mild to severe hemophilia with joint pain and/or bleeding completed a pain history survey and 5 patient-reported outcome instruments assessing pain, functional impairment and health-related quality of life during comprehensive care visits to be included in the study. Results presented at THSNA were of the full study population of 381 males enrolled between October 2013 to October 2014. Results showed that approximately two-thirds of participants experienced chronic pain (with or without acute pain) in the past 6 months. Participants had a median age of 34, about 2/3 (65%) were overweight or obese, and included patients with hemophilia A (77%), B (23%) or inhibitors (9%) from 15 US HTCs. Most participants reported having acute (bleed related) and/or chronic (arthritic) pain in the past 6 months with 2/3 reporting chronic pain in the past 6 months; only 15% reported no pain. Ankles were most commonly reported as the most painful joints (37%) followed by knees (24%) and elbows (19%). Sharp and aching were the two most common descriptors of pain. Terms more commonly used for acute pain (compared with chronic pain) were sharp, stabbing and burning. Terms more commonly used to describe chronic pain were aching, nagging, and tiring. Factor replacement and bypassing agents were reported by half (51%) of all participants as an acute pain treatment. Nonsteroidal anti-inflammatory agents (NSAIDs) were more commonly reported for chronic pain. Ice, rest, elevation and compression (RICE) were commonly reported physical approaches.
The PFiQ study (NCT01988532) was sponsored by Novo Nordisk Inc.